Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preserved vs Preservative-free Latanoprost in Glaucoma and Ocular Hypertension
NCT05606796Phase 4Unknown
- Start
- Dec 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of latanoprost ophthalmic solution 0.005% (TearClear TC-002) in primary open-angle glaucoma (POAG), ocular hypertension. Status: unknown.
02
Drugs
latanoprost ophthalmic solution 0.005% (TearClear TC-002)
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT05606796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05606796.